Gujarat Inject (Kerala) Limited (GUJINJEC) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.9B
Fair value as of: Jul 5, 2026
From 25 valuation models · updated today
Share price +14.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹19.96 – ₹130.90 · fair‑value band ₹11.36 – ₹28.26 · the ₹130.90 price screens above the ₹21.05 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Gujarat Inject (Kerala) Limited (GUJINJEC) currently trades at ₹130.90, while our model-based Fair Value estimate is ₹21.05 — implying the stock looks roughly 83.9% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Gujarat Inject (Kerala) Limited generated revenue of ₹365M at a net margin of 5.0%. It earns a return on equity of 16.6%. Net debt stands at ₹5.5M. The stock trades on a trailing P/E of 105.6. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹11.36 (bear case) to ₹28.26 (bull case); at ₹130.90, the current price sits above that range. The share trades about 4% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -84%, GUJINJEC screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Gujarat Inject (Kerala) Limited engages in the business of trading of goods. The company was incorporated in 1991 and is based in Vadodara, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Gujarat Inject (Kerala) Limited reported revenue of ₹363M in FY2026 versus ₹226K in FY2022, a compound +533.2%/yr. Reported net income was ₹18.1M in FY2026, compounding +435.3%/yr from FY2022.
Is GUJINJEC fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gujarat Inject (Kerala) Limited (GUJINJEC) undervalued?
What is the fair value of GUJINJEC?
What is the quality score of GUJINJEC?
What is the revenue of Gujarat Inject (Kerala) Limited (GUJINJEC)?
What is the net profit margin of GUJINJEC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.